Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study

Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study

ObjectiveComparing the efficacy of transarterial chemoembolization (TACE) combined with lenvatinib plus tislelizumab (TLT) with TACE combined with lenvatinib (TL) for unresectable hepatocellular carcinoma, particularly in determining which patients can benefit more from the TLT treatment.MethodsFrom...

Full description

Bibliographic Details
Main Authors: Yushan Zhao, Shuwei Wen, YaoQing Xue, Zhijun Dang, ZhiYu Nan, Dong Wang, Xiao Li, Duiping Feng, Yi Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Immunology
Subjects:
TACE
lenvatinib
tislelizumab
hepatocellular carcinoma
overall survival
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1449663/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1449663/full

Similar Items